Brachytherapy: Update and results

Current Urology Reports

Volumn 4, Issue 3, 2003, Pages 233-239

  Ellis, Rodney J ^a   Kim, Edward ^a  

^a AULTMAN HOSPITAL   (United States)

Author keywords

Combination Therapy Group; Gleason Score; Prostate Brachytherapy; Prostate Cancer; Radiat Oncol Biol Phys

Indexed keywords

BRACHYTHERAPY; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PROSTATE TUMOR; REVIEW;

BRACHYTHERAPY; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PROSTATIC NEOPLASMS;

EID: 0042911878     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-003-0075-2     Document Type: Article

References (45)

1. American Cancer Society: Cancer Facts and Figures: 2002. Atlanta: American Cancer Society; 2002.
2. Barringer BS: Radium in the treatment of carcinoma of the bladder and prostate. JAMA 1917, 68:1227–1230.
3. Charyulu KKN: Transperineal interstitial implantation of prostate cancer: a new method. Int J Radiat Oncol Biol Phys 1980, 6:1261–1266.
4. Kumar PP, Bartone FF: Transperineal percutaneous I-125 implant of the prostate. Urology 1981, 17:238–240. DOI: 10.1016/0090-4295(81)90037-6
5. Holm HH, Juul N, Pedersen JF, et al.: 125-Iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983 130:283–286.
6. Nag S: Transperineal iodine-125 implantation of the prostate under transrectal ultrasound and fluoroscopic control. Endocurie Hyperthermi Oncol 1985, 1:207–211.
7. Ling CC: Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992, 23:81–87.
8. Blasko JC, Grimm PD, Ragde H: Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993, 3:240–249. DOI: 10.1016/S1053-4296(05)80121-3
9. Wallner K, Merrick G, True L, et al.: I-125 versus Pd-103 for lowrisk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002, 8:67–73. DOI: 10.1097/00130404-200201000-00012
10. Wallner KE, Roy J, Harrison L: Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995, 32:465–471. DOI: 10.1016/0360-3016(94)00599-G
11. Wallner K, Blasko J, Dattoli M: Evaluation. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: SmartMedicine Press; 1997:10.1–10.27.
12. Zelefsky MJ, Leibel SA, Gaudin PB, et al.: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 41:491–500. DOI: 10.1016/S0360-3016(98)00091-1
13. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, et al.: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002 52:429–438. DOI: 10.1016/S0360-3016(01)02609-8
14. Wright GL, Haley C, Beckett ML, et al.: Expression of prostatespecific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995, 1:18–28.
15. Silver DA, Pellicer I, Fair WR, et al.: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3:81–85.
16. Ellis RJ, Sodee DB, Spirnak JP, et al.: Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 48:483–487. DOI: 10.1016/S0360-3016(00)00646-5
17. Ellis RJ, Kim EY, Conant R, et al.: Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. Int J Radiat Oncol Biol Phys 2001, 49:1281–1286. DOI: 10.1016/S0360-3016(00)01582-0
18. Wallner K, Blasko J, Dattoli M: Implant alone vs. implant+EBRT. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:12.1–12.29.
19. D’Amico AV, Coleman CN: Role of radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol 1996, 14:304–315.
20. Nag S, Beyer D, Friedland J, et al.: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789–799. DOI: 10.1016/S0360-3016(99)00069-3
21. Wallner K, Blasko J, Dattoli M: Who can’t have an implant? In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:13.1–13.11.
22. Wallner K, Lee H, Wasserman S, Dattoli M: Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997, 37:565–569. DOI: 10.1016/S0360-3016(96)00570-6
23. Wallner K, Blasko J, Dattoli M: Implant alone vs. implant+EBRT. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:12.1–12.29.
24. Wallner K, Blasko J, Dattoli M. Morbidity. In Prostate Brachytherapy Made Complicated. Edited by Wallner K, Blasko J, Dattoli M. Seattle: Smart Medicine Press; 1997:16.1–16.17.
25. Hu K, Wallner KE: Urinary incontinence in patients who have TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998, 40:783–786. DOI: 10.1016/S0360-3016(97)00928-0
26. Wallner K: Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. Oncology 1991, 5:115–126.
27. Consensus statement: Guidelines for PSA following Radiation Therapy. Int J Radiat Oncol Biol Phys 1997, 37:1035–1041.
28. Grado GL, Larson TR, Balch CS, et al.: Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998, 42:289–298. DOI: 10.1016/S0360-3016(98)00209-0
29. Zelefsky MJ, Hollister T, Raben A, et al.: Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 47:1261–1266. This paper describes the MSKCC experience with brachytherapy as monotherapy and details the method that many other centers use for stratifying implant patients by number of risk factors. DOI: 10.1016/S0360-3016(00)00550-2
30. Ragde H, Elgamal A, Snow P, et al.: Ten-year disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998, 83:989–1001. DOI: 10.1002/(SICI)1097-0142(19980901)83:5<989::AID-CNCR26>3.0.CO;2-Q
31. Ragde H, Korb LJ, Elgamal AA, et al.: Modern prostate brachytherapy: prostate specific antigen results in 219 patients with up to 12 years of observed follow up. Cancer 2000, 89:135–141. This paper describes the Seattle experience with seed implants and provides some of the longest published follow-up data available. DOI: 10.1002/1097-0142(20000701)89:1<135::AID-CNCR18>3.0.CO;2-#
32. Blasko JC: An update on LDR permanent brachytherapy for prostate cancer. Presented at the 21st Annual Meeting of the American Brachytherapy Society. San Diego: May 23–25,1999.
33. Blasko JC, Grimm PD, Sylsvester JE, et al.: The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000, 57:273–278. DOI: 10.1016/S0167-8140(00)00288-7
34. Ellis RJ: Four-year biochemical outcome following radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Presented at the RSNA 88th Scientific Assembly and Annual Meeting. Chicago: December 1–6, 2002.
35. Merrick GS, Butler WM, Galbreath RW, et al.: Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001, 51:41–48. This group in West Virginia plans implants with larger treatment volumes than many other centers, but also publishes data showing excellent long-term disease control. DOI: 10.1016/S0360-3016(01)01594-2
36. Dattoli M, Wallner K, Sorace R, et al.: 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996, 35:875–879. DOI: 10.1016/0360-3016(96)00214-3
37. Merrick GD, Butler WM, Lief JH, et al.: Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. Brachytherapy 2002, 1:95–101. This paper reports excellent 6-year results for patients treated with a combination of external beam radiation and seed implant. DOI: 10.1016/S1538-4721(02)00016-8
38. Grimm PD, Blasko JC, Sylvester JE, et al.: 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys 2001, 51:31–40. DOI: 10.1016/S0360-3016(01)01601-7
39. Kwok Y, Dibiase SJ, Amin PP, et al.: Risk group stratification in patients undergoing permanent 125I brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002, 53:588–594. DOI: 10.1016/S0360-3016(02)02796-7
40. Stock RG, Stone NN: The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 1997, 13:454–460. DOI: 10.1002/(SICI)1098-2388(199711/12)13:6<454::AID-SSU10>3.0.CO;2-T
41. Critz FA: A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 2002, 167:1310–1313. DOI: 10.1016/S0022-5347(05)65288-3
42. Ellis RJ: Combination conformal radiotherapy and radioimmunoguided transperineal Pd-103 implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Presented at the 11th Annual International Brachytherapy Conference. Santa Fe: June 5, 2002.
43. Lederman GS, Cavanagh W, Albert PS, et al.: Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 2001, 49:1297–1303. DOI: 10.1016/S0360-3016(00)01442-5
44. Singh A, Zelefsky MJ, Raben A, et al.: Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Int J Cancer (Radiat Oncol Invest) 2000, 90:275–280. This paper details the MSKCC experience with combination therapy for intermediate- and high-risk prostate cancer. DOI: 10.1002/1097-0215(20001020)90:5<275::AID-IJC4>3.0.CO;2-M
45. Zeitlin SI, Sherman J, Raboy A, et al.: High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998, 160:91–96. DOI: 10.1016/S0022-5347(01)63042-8